首页> 外文OA文献 >Induction of Immune Responses in Mice after Oral Immunization with Recombinant Lactobacillus casei Strains Expressing Enterotoxigenic Escherichia coli F41 Fimbrial Protein▿
【2h】

Induction of Immune Responses in Mice after Oral Immunization with Recombinant Lactobacillus casei Strains Expressing Enterotoxigenic Escherichia coli F41 Fimbrial Protein▿

机译:表达肠毒素的大肠杆菌F41纤维蛋白的重组干酪乳杆菌菌株口服免疫后诱导小鼠的免疫反应

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

In an effort to develop a safe and effective vaccine for the prevention of enterotoxigenic Escherichia coli (ETEC) F41 infections, we have developed a surface antigen display system using poly-γ-glutamate synthetase A (PgsA) as an anchoring matrix. The recombinant fusion proteins comprised of PgsA and fimbrial protein of F41 were stably expressed in Lactobacillus casei 525. Surface localization of the fusion protein was verified by immunoblotting, immunofluorescence microscopy, and flow cytometry. Oral inoculation of recombinant L. casei 525 into specific-pathogen-free BALB/c mice resulted in significant mucosal immunoglobulin A (IgA) titers that remained elevated for >16 weeks. High levels of IgG responses in sera specific for F41 fimbriae were also induced, with prominent IgG1 titers as well as IgG2a and IgG2b titers. The helper T-cell (Th) response was Th2-cell dominant, as evidenced by increased mucosal and systemic interleukin-4-producing T cells and a concomitant elevation of serum IgG1 antibody responses. More than 80% of the mice were protected against challenge with a 2 × 104-fold 50% lethal dose of standard-type F41 (C83919). The induced antibodies were important for eliciting a protective immune response against F41 infection. These results indicated that the use of recombinant L. casei 525 could be a valuable strategy for future vaccine development for ETEC.
机译:为了开发一种安全有效的疫苗来预防肠毒素性大肠杆菌(ETEC)F41感染,我们开发了一种表面抗原展示系统,该系统使用聚-γ-谷氨酸合成酶A(PgsA)作为锚定基质。由PgsA和F41纤维蛋白组成的重组融合蛋白在干酪乳杆菌525中稳定表达。通过免疫印迹,免疫荧光显微镜和流式细胞术验证了融合蛋白的表面定位。将重组干酪乳杆菌525口服接种到无特定病原体的BALB / c小鼠中会导致明显的粘膜免疫球蛋白A(IgA)滴度,并持续升高> 16周。还诱导了F41菌毛特异的血清中高水平的IgG应答,其中IgG1滴度以及IgG2a和IgG2b滴度都很高。辅助性T细胞(Th)应答以Th2细胞为主,这由粘膜和全身性白介素4产生性T细胞的增加以及血清IgG1抗体应答的同时升高所证明。用2×104倍50%致死剂量的标准型F41(C83919)保护了80%以上的小鼠免受攻击。诱导的抗体对于引发针对F41感染的保护性免疫应答非常重要。这些结果表明,重组干酪乳杆菌525的使用可能是将来开发ETEC疫苗的有价值的策略。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号